Efficacy of Adjuvant Low Dose Rituximab and Plasma Exchange for Acquired TTP with Severe ADAMTS13 Deficiency -- Results of the ART Study

Conclusions:These results with low dose rituximab (100 mg x 4 doses) are consistent with reports that immediate treatment of TTP with standard dose rituximab (375 mg/m2x 4 doses) reduces the incidence of exacerbation and refractory disease, and prevents or delays relapses. A direct comparison of these regimens would be useful to establish whether low dose rituximab has similar efficacy with greater ease of administration, less cost, and less risk of infusion reactions and late complications.DisclosuresSadler: Ablynx: Consultancy. Zwicker: Quercegen: Research Funding; Daiichi: Honoraria; Parexel: Consultancy; Incyte: Research Funding.

Source: Blood - November 21, 2018 Category: Hematology Authors: Sadler, J. E., Muia, J., Dolatshahi, L., Westfield, L. A., Nieters, P., Rodrigues, A., Antun, A. G., Metjian, A., Zwicker, J. I. Tags: 311. Disorders of Platelet Number or Function: Advances in the Treatment of TTP and HIT Source Type: research